Advanced in Aplastic Anemia

Dr. Alvaro Moreno-Aspitia

Hematology Oncology | Hematology | Oncology
4500 San Pablo Rd S, 
Jacksonville, FL 
Advanced in Aplastic Anemia
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alvaro Moreno-Aspitia is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Moreno-Aspitia is rated as an Advanced provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: FASN Inhibitor TVB-2640, Paclitaxel, Trastuzumab
Study Phase: Phase 2
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Therapeutic Estradiol
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Procedure, Other
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drugs: Anastrozole, Letrozole
Study Phase: Phase 2
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Palbociclib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy
Enrollment Status: Completed
Publish Date: June 01, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

74 Total Publications

Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2024
Similar Doctors
Distinguished in Aplastic Anemia
Dr. Candido Rivera
Hematology
Distinguished in Aplastic Anemia
Dr. Candido Rivera
Hematology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, Mcj Advanced Care At Home, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Candido Rivera is a Hematologist in Jacksonville, Florida. Dr. Rivera is rated as an Advanced provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Aplastic Anemia, Sickle Cell Disease, Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Aplastic Anemia
Dr. Ernesto Ayala
Hematology | Hematology Oncology | Transplant Surgery
Advanced in Aplastic Anemia
Dr. Ernesto Ayala
Hematology | Hematology Oncology | Transplant Surgery

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ernesto Ayala is a Hematologist and a Hematologist Oncology provider in Jacksonville, Florida. Dr. Ayala is rated as a Distinguished provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Non-Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ayala is currently accepting new patients.

Advanced in Aplastic Anemia
Dr. Jorge C. Antunez-De
Hematology Oncology | Hematology | Oncology
Advanced in Aplastic Anemia
Dr. Jorge C. Antunez-De
Hematology Oncology | Hematology | Oncology

Baptist MD Anderson Cancer Physicians Inc

1301 Palm Ave, 
Jacksonville, FL 
 (13.6 miles away)
904-202-7300
Languages Spoken:
English, French, Italian, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jorge Antunez-De is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Antunez-De is rated as an Advanced provider by MediFind in the treatment of Aplastic Anemia. His top areas of expertise are Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Hemangioma Thrombocytopenia Syndrome, and Childhood Iron Deficiency Anemia. Dr. Antunez-De is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moreno-Aspitia's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile